Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop.

@article{Roberts2016ChallengesAO,
  title={Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop.},
  author={Jeffrey N Roberts and Barney S. Graham and Ruth A. Karron and Flor M Munoz and Ann R. Falsey and Larry J. Anderson and Valerie Marshall and Sonnie Kim and Judy A Beeler},
  journal={Vaccine},
  year={2016},
  volume={34 41},
  pages={
          4843-4849
        }
}
Respiratory syncytial virus (RSV) is the most common cause of serious acute lower respiratory illness in infants and young children and a significant cause of disease burden in the elderly and immunocompromised. There are no licensed RSV vaccines to address this significant public health need. While advances in vaccine technologies have led to a recent resurgence in RSV vaccine development, the immune correlates of protection against RSV and the immunology of vaccine-associated enhanced… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

SEVERE VIRAL RESPIRATORY TRACT INFECTIONS

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Towards the Application of Human Defensins as Antivirals

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Original Antigenic Sin and Respiratory Syncytial Virus Vaccines

VIEW 2 EXCERPTS
CITES BACKGROUND

Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016

VIEW 1 EXCERPT
CITES BACKGROUND